Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys... 
Via Benzinga
Exposures COVID-19
3 Ultra-High-Yield Dividend Stocks Billionaires Are Sinking Their Teeth Into
Prominent billionaire money managers are piling into three industry-leading businesses with supercharged yields ranging from 6% to 15.1%! 
Via The Motley Fool
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Check Out What Whales Are Doing With PFE
Via Benzinga
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
3 Hidden-Gem Value Stocks to Buy and Never Let Go
Here are three top hidden-gem value stocks long-term investors would do well to consider on any meaningful dips moving forward. 
Via InvestorPlace
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Dive into the fundamentals behind the resilience of recession-proof stocks and the performance indicators driving their success. 
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
After the FDA's authorization of a Covid19 booster shot, you may want to consider adding these vaccine stocks to your portfolio. 
Via InvestorPlace
Exposures Product Safety
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
These high-yield dividend payers have what it takes to pump up your portfolio's passive income stream. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These pharma and biotech players could become long-term winners. 
Via The Motley Fool
Masters In Trading - Saturday, June 8
In this video, I review the most recent trading session. I also discuss what a trader's 
Via Talk Markets
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
2 Dividend Stocks Billionaires Are Buying: Should You?
That's not a bad crowd to follow when investing in stocks. 
Via The Motley Fool
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze. 
Via InvestorPlace
Exposures COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Why Is Novavax (NVAX) Stock Up 20% Today?
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock. 
Via InvestorPlace
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 
From Relay Therapeutics, Inc.
Via GlobeNewswire
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Right Now
These two high-yield dividend stocks are top buys right now. 
Via The Motley Fool
Alphabet, Ventas, ASML And A Pharmaceutical Giant On CNBC's 'Final Trades'
Alphabet recently declared a $2 billion investment plan to establish its inaugural data center and Google Cloud region in Malaysia. 
Via Benzinga
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Investors shouldn't expect a big improvement in Pfizer's financials this year. 
Via The Motley Fool
7 Dividend Stocks to Invest In for a Lifetime of Income
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment. 
Via InvestorPlace
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.